Dose-response relationship of topically applied methylprednisolone aceponate (MPA) in healthy volunteers
- PMID: 1425873
- DOI: 10.1007/BF01740663
Dose-response relationship of topically applied methylprednisolone aceponate (MPA) in healthy volunteers
Abstract
Topical glucocorticosteroids are useful in the treatment of various skin diseases. Although many corticosteroids are available today, there is still a need for highly potent compounds with minimal adverse effects. Methylprednisolone aceponate (MPA) has recently been synthesized. Its activity has been evaluated using the vasoconstrictor assay and the poison ivy test (rhus dermatitis) in 19/20 healthy volunteers of either sex. Comparable blanching was found with MPA in a cream vehicle, in an ointment and a fatty ointment. Vasoconstriction and suppression of experimentally-induced poison ivy contact dermatitis were dose-dependent in the concentration range 0.01% to 0.5% MPA. Concentrations of MPA of at least 0.05% were significantly active. Following the highest dose, blanching was close to the maximum which can be obtained. This finding, and the improvement of rhus dermatitis, suggest that MPA belongs to the highly potent local glucocorticosteroids.
Similar articles
-
Activity of topically applied methylprednisolone aceponate in relation to other topical glucocorticosteroids in healthy volunteers.Arzneimittelforschung. 1993 Feb;43(2):144-7. Arzneimittelforschung. 1993. PMID: 8457237 Clinical Trial.
-
Local tolerability of topically applied methylprednisolone aceponate.J Am Acad Dermatol. 1993 May;28(5 Pt 1):786-8. doi: 10.1016/s0190-9622(09)80275-2. J Am Acad Dermatol. 1993. PMID: 8496430 Clinical Trial. No abstract available.
-
Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal antiinflammatory activity.J Am Acad Dermatol. 1993 Oct;29(4):576-80. doi: 10.1016/0190-9622(93)70224-h. J Am Acad Dermatol. 1993. PMID: 8408793 Clinical Trial.
-
Methylprednisolone aceponate in eczema and other inflammatory skin disorders -- a clinical update.Int J Clin Pract. 2006 Jan;60(1):85-92. doi: 10.1111/j.1368-5031.2005.00754.x. Int J Clin Pract. 2006. PMID: 16409433 Review.
-
Methylprednisolone aceponate for atopic dermatitis.Int J Dermatol. 2017 Jun;56(6):691-697. doi: 10.1111/ijd.13485. Epub 2017 Mar 4. Int J Dermatol. 2017. PMID: 28258632 Review.
Cited by
-
Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept.Drug Saf. 1996 Jun;14(6):375-85. doi: 10.2165/00002018-199614060-00003. Drug Saf. 1996. PMID: 8828015 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources